Signature [CONTACT_66726]-IQ Technology in Individuals with Type 2 Diabetes (2IQ) Protocol Identifying Number: TP-0009569 IND/IDE Sponsor: Tandem Diabetes Care, Inc. Version Number: v. 3.[ADDRESS_600339] 2021  JCHR Protocol Director   Name, degree  John Lum, M S / Jaeb Center for Health Research  Signature/Date    Sponsor  Tandem Diabetes Care, Inc.  Name, degree  Jordan Pi[INVESTIGATOR_3388], M.D.  Signature/Date    Clinical Lead Investigator   Name, degree  Carol Levy, M.D.  / Icahn School of Medicine at Mount Sinai  Signature/Date    Medical Monitor   Name, degree  Roy Beck, MD, Ph.D. / Jaeb Center for Health Research  Signature/Date    
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 2 OF 58 Control-IQ Technology in Individuals with Type 2 Diabetes (2IQ) Protocol Identifying Number: TP-0009569 IND/IDE Sponsor: Tandem Diabetes Care, Inc.   Version Number: v3.[ADDRESS_600340] 2021  
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 3 OF 58 KEY ROLES  Protocol Chair/Director   Name, degree  Carol Levy, M.D.  Institution Name  [CONTACT_468518], degree  John Lum, MS  Institution Name  [CONTACT_468519], degree  Roy Beck, M.D., Ph.D.  Institution Name  [CONTACT_468520], degree  Jordan Pi[INVESTIGATOR_3388], M.D.  Institution Name  [CONTACT_3438], Inc.  
[ADDRESS_600341]  
San Diego, CA [ZIP_CODE]   
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0  PAGE 4 OF 58 TABLE OF CONTENTS CHAPTER 1: BACKGROUND INFORMATION ............................................................................................. 15 1.1 Disease Background .......................................................................................................................... 15 1.2 Device Background ........................................................................................................................... 15 1.3 Rationale ............................................................................................................................................ 16 1.4 Potential Risks and Benefits of the Investigational Device ............................................................... 16 1.4.1 Known Potential Risks ................................................................................................................ 16 [IP_ADDRESS] Potential Risks and Benefits of the CLC System ................................................................ 16 [IP_ADDRESS] Risk of Hypoglycemia ........................................................................................................ 16 [IP_ADDRESS] Risk of Hyperglycemia ....................................................................................................... 17 [IP_ADDRESS] Fingerstick Risks ................................................................................................................. 17 [IP_ADDRESS] Venipuncture Risks ............................................................................................................. 17 [IP_ADDRESS] Subcutaneous Catheter Risks .............................................................................................. 17 [IP_ADDRESS] Risk of Exercise .................................................................................................................. 17 [IP_ADDRESS] Risk of Device Reuse .......................................................................................................... 18 [IP_ADDRESS] Questionnaires and Semi-Structured Interviews ................................................................. 18 [IP_ADDRESS] Other Risks ........................................................................................................................ 18 1.4.2 Known Potential Benefits ............................................................................................................ 18 1.4.3 Risk Assessment .......................................................................................................................... 18 1.5 General Considerations...................................................................................................................... 19 CHAPTER 2: STUDY ENROLLMENT AND SCREENING .............................................................................. 20 2.1 Participant Recruitment and Enrollment ........................................................................................... 20 2.1.1 Informed Consent and Authorization Procedures ....................................................................... 20 2.2 Participant Inclusion Criteria ............................................................................................................. 20 2.3 Participant Exclusion Criteria ............................................................................................................ 21 2.4 Screening Procedures ........................................................................................................................ 22 2.4.1 Data Collection and Testing ........................................................................................................ 22 2.5 Screen Failures .................................................................................................................................. 23 CHAPTER 3: CGM AND PUMP RUN-IN PHASES ....................................................................................... 24 3.1 CGM Run-in Phase Overview ........................................................................................................... 24 3.2 Initiation of CGM .............................................................................................................................. 24 3.2.1 CGM Training ............................................................................................................................. 24 3.3 Blood Glucose and Blood Ketone Testing ........................................................................................ 25 3.4 Assessment of Successful Completion of the CGM Run-in Phase ................................................... 25 3.5 Pump Run-in Phase Overview ........................................................................................................... 26 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0  PAGE 5 OF 58 3.6 Initiation of the Study Pump .............................................................................................................. 26 3.6.1 Study Pump Training ................................................................................................................... 26 3.6.2 Initiation of Pump by [CONTACT_3427] ...................................................................................... 27 3.6.3 System Use Guidelines ................................................................................................................ 27 3.7 Blood Glucose Testing ...................................................................................................................... 28 3.8 Assessment of Successful Completion of the Pump Run-in Phase ................................................... 28 3.9 Optimization of Insulin Therapy ....................................................................................................... 28 CHAPTER 4: CONTROL-IQ (CLOSED-LOOP) PHASE ............................................................................... [ADDRESS_600342]-Study Call ............................................................................................................... 33 4.1.11 Exercise Challenge Follow-Up .................................................................................................. 33 4.2 Early Termination Visit (If Applicable) ............................................................................................ 33 4.3 Unscheduled Visits ............................................................................................................................ 33 CHAPTER 5: STUDY DEVICES .................................................................................................................... 34 5.1 Description of the Investigational Device ......................................................................................... 34 5.1.1 Insulin Pump ................................................................................................................................ 34 5.1.2 Continuous Glucose Monitoring ................................................................................................. 34 5.1.3 Blood Glucose Meter and Strips .................................................................................................. 34 5.1.4 Ketone Meter ............................................................................................................................... 34 5.1.5 Study Device Accountability Procedures .................................................................................... 34 5.2 Safety Measures ................................................................................................................................. 34 5.2.1 CGM Calibration ......................................................................................................................... 34 5.2.2 Pump Failure ............................................................................................................................... 34 5.2.3 Hypoglycemia Threshold Alarm and Safety Protocol ................................................................. 34 5.2.4 Hyperglycemia Threshold Alarm and Safety Protocol ................................................................ 35 5.3 Participant Access to Study Device at Study Closure ....................................................................... 35 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0  PAGE 6 OF 58 CHAPTER 6: TESTING PROCEDURES AND QUESTIONNAIRES ................................................................. 36 6.1 Laboratory Testing ............................................................................................................................ 36 6.2 Electrocardiogram (ECG) .................................................................................................................. 36 6.3 Questionnaires ................................................................................................................................... 36 6.4 Semi-Structured Interviews ............................................................................................................... 37 CHAPTER 7: UNANTICIPATED PROBLEM, ADVERSE EVENT, AND DEVICE ISSUE REPORTING ............ 38 7.1 Unanticipated Problems ..................................................................................................................... 38 7.2 Adverse Events .................................................................................................................................. 38 7.2.1 Definitions ................................................................................................................................... 38 7.2.2 Reportable Adverse Events ......................................................................................................... 40 7.2.3 Hypoglycemic Events .................................................................................................................. 40 7.2.4 Hyperglycemic/Ketotic Events .................................................................................................... 41 7.2.5 Relationship of Adverse Event to Study Investigational Device ................................................. 42 7.2.6 Severity (Intensity)  of Adverse Events ....................................................................................... 43 7.2.7 Expectedness ............................................................................................................................... 43 7.2.8 Coding of Adverse Events ........................................................................................................... 43 7.2.9 Outcome of Adverse Events ........................................................................................................ 43 7.3 Reportable Device Issues ................................................................................................................... 44 7.4 Timing of Event Reporting ................................................................................................................ 44 7.5 Safety Oversight ................................................................................................................................ 45 7.6 Stoppi[INVESTIGATOR_2121] ............................................................................................................................... 45 7.6.1 Participant Discontinuation of Study Device .............................................................................. 45 7.6.2 Criteria for Suspending or Stoppi[INVESTIGATOR_3396] ..................................................................... 46 CHAPTER 8: MISCELLANEOUS CONSIDERATIONS ................................................................................... 47 8.1 Drugs Used as Part of the Protocol .................................................................................................... 47 8.2 Collection of Medical Conditions and Medications .......................................................................... 47 8.3 Prohibited Medications, Devices, Treatments, and Procedures ......................................................... 47 8.4 Precautionary Medications, Treatments, and Procedures .................................................................. 48 8.5 Prophylactic Medications, Treatments, and Procedures .................................................................... 48 8.6 Rescue Medications, Treatments, and Procedures ............................................................................ 48 8.7 Pregnancy Reporting ......................................................................................................................... 48 8.8 Participant Compensation .................................................................................................................. 48 8.9 Participant Withdrawal ...................................................................................................................... 48 8.10 Confidentiality ................................................................................................................................. 48 CHAPTER 9: STATISTICAL CONSIDERATIONS ...................................... ERROR! BOOKMARK NOT DEFINED. 9.1 Statistical and Analytical Plans ......................................................... Error! Bookmark not defined. 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0  PAGE 7 OF 58 9.2 Statistical Hypotheses ........................................................................ Error! Bookmark not defined. 9.3 Sample Size ....................................................................................... Error! Bookmark not defined. 9.4 Outcome Measures ............................................................................ Error! Bookmark not defined. 9.4.1 Primary Efficacy Endpoints ........................................................ Error! Bookmark not defined. 9.4.2 Secondary Efficacy Endpoints .................................................... Error! Bookmark not defined. 9.4.3 Safety Endpoints .......................................................................... Error! Bookmark not defined. 9.5 Analysis Datasets and Sensitivity Analyses ...................................... Error! Bookmark not defined. 9.6 Analysis of the Primary Efficacy Endpoint(s) ................................... Error! Bookmark not defined. 9.7 Analysis of the Secondary Endpoint.................................................. Error! Bookmark not defined. 9.8 Safety Analyses ................................................................................. Error! Bookmark not defined. 9.9 Intervention Adherence ..................................................................... Error! Bookmark not defined. 9.10 Protocol Adherence and Retention .................................................. Error! Bookmark not defined. 9.11 Baseline Descriptive Statistics ......................................................... Error! Bookmark not defined. 9.12 Device Issues ................................................................................... Error! Bookmark not defined. 9.13 Planned Interim Analyses ................................................................ Error! Bookmark not defined. 9.14 Sub-Group Analyses ........................................................................ Error! Bookmark not defined. 9.15 Multiple Comparison/Multiplicity ................................................... Error! Bookmark not defined. 9.16 Exploratory Analyses ...................................................................... Error! Bookmark not defined. CHAPTER 10: DATA COLLECTION AND MONITORING ............................................................................ 49 10.1 Case Report Forms and Other Data Collection ............................................................................... 54 10.2 Study Records Retention ................................................................................................................. 54 10.3 Quality Assurance and Monitoring .................................................................................................. 54 10.4 Protocol Deviations ......................................................................................................................... 55 CHAPTER 11: ETHICS/PROTECTION OF HUMAN PARTICIPANTS ............................................................ [ADDRESS_600343] ............................................................................................................................... 56 11.2 Institutional Review Boards ............................................................................................................ 56 11.3 Informed Consent Process ............................................................................................................... 56 11.3.1 Consent Procedures and Documentation ................................................................................... 56 11.3.2 Participant and Data Confidentiality ......................................................................................... 56 CHAPTER 12: REFERENCES ....................................................................................................................... [ADDRESS_600344] OF ABBREVIATIONS ABBREVIATION  DEFINITION  AE Adverse Event  AID Automated Insulin Dosing  AUC  (Glucose) Area under the curve  CGM  Continuous Glucose Monitoring  CRF  Case Report Form  Control -IQ System  t:slim X2 insulin pump with Control -IQ technology  CSII  Continuous Subcutaneous Insulin Infusion  DCA2000  Siemens/Bayer DCA 2000+ Hematology A nalyzer  DKA  Diabetic Ketoacidosis  eCRF  Electronic Case Report Form  EDC  Electronic Data Capture  ECG  Electrocardiogram  FDA  [LOCATION_002] Food and Drug Administration  HbA1c  Hemoglobin A1c  HCL  Hybrid Closed -loop  HHS  Hyperosmolar Hyperglycemic Syndrome  ICF Informed Consent Form  IDE Investigational Device Exemption  MDI  Multiple Daily Injections of insulin  POC  Point -Of-Care  QC Quality Control  QoL Quali ty of Life  SD Standard Deviation  T2D Type 2 diabetes  TDD  Total Daily Dose of insulin  TIR Time in range   
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 9 OF 58 SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_468503]: Control-IQ Technology in Individuals with Type 2 Diabetes (2IQ) Protocol Version/Date: 3.0 / [ADDRESS_600345] read the protocol specified above.  In my formal capacity as a Site Principal Investigator, my duties include ensuring the safety of the study participants enrolled under my supervision and providing the Jaeb Center for Health Research, which serves as the Coordinating Center for the protocol, with complete and timely information, as outlined in the protocol.  It is understood that all information pertaining to the study will be held strictly confidential and that this confidentiality requirement applies to all study staff at this site. This trial will be carried out in accordance with the principles of Good Clinical Practice (GCP) and as required by [CONTACT_716] (use applicable regulations depending on study location and sponsor requirements; examples follow): [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812). As the Principal Investigator, I will assure that no deviation from, or changes to the protocol will take place without prior agreement from the sponsor and documented approval from the Institutional Review Board (IRB), or other approved Ethics Committee, except where necessary to eliminate an immediate hazard(s) to the trial participants. All key personnel (all individuals responsible for the design and conduct of this trial) have completed Human Participants Protection Training and Good Clinical Practice Training.  Further, I agree to ensure that all staff members involved in the conduct of this study are informed about their obligations in meeting the above commitments. Investigator’s Signature __________________________________ Date: _____ / _____ / _____  dd mmm yyyy Investigator’s Name: ____________________________________ Site Name/Number: _____________________________________  
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 10 OF 58 PROTOCOL SUMMARY PARTICIPANT AREA  DESCRIPTION  Title  Control -IQ Technology in Individuals with Type 2 Diabetes  (2IQ)  Précis A prospective, single -arm study of 6 weeks of home use of the Control -IQ 
automated insulin delivery system  in individuals with type 2 diabetes  age 
18 and older . Investigational Device  t:slim X2 insulin pump with Control -IQ technology v1.5 (Control -IQ 
System)  Objectives  The objective s of the study are to assess  safety  and explore glycemic 
outcomes with use of  a closed loop control (CLC) system (t:slim X2 with 
Control -IQ Technology) in adults with type 2 diabetes  to provide data to 
design a subsequent larger stu dy. Study Design  After an initial run -in period to ensure that participants can successfully 
use the study CGM and study pump  in open -loop mode, a ll participants 
will use the study system (pump and CGM) in closed -loop mode for 6 
weeks.  Number of Sites  ~3 US clinical centers  Key Safety Endpoint s Key Safety  Endpoints : 
• Severe Hypoglycemia  
• Diabetic Ketoacidosis  and Hyperos molar Hyperglycemic  Syndrome  
• Other r eportable adverse events  (see section 7.2.2 )  
• Unanticipated adverse device effects  
 Other Endpoints  Other Endpoints : 
• CGM -measured % below 54 mg/dl  
• CGM -measured % above 180 mg/dL  
• CGM -measured p ost-prandial glycemic peak  
• Various other CGM -measured glycemic outcomes over [ADDRESS_600346] to 
announced meals  
• Total daily insulin use, daily basal and bolus insulin, and Weight  
Primary and secondary endpoints will be analyzed in total together, as 
well as separately for Group A (prior users of basal insulin only) and 
Group B (prior users of multiple daily injections) participants.  Population  Inclusion Criteria  
1. Age ≥[ADDRESS_600347] 3 months, to include A) basal 
insulin only, or B) MDI, to include CSII  (including use of  AID 
system s other than Tandem Control -IQ) 
4. Total daily insulin dose ≤200 units/day  
5. Willing to use only aspart (novolog) or lispro (humalog) insulin with 
the study pump , with no use of concentrated insulin above U -100, 
long-acting basal insulin injection s, or inhaled insulin  
6. For females, not currently known to be pregnant  
If female of child -bearing potential , must agree to use a form of 
contraception to prevent pregnancy while a participant in the study  
as documented in the study records . A negative serum or urine 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.[ADDRESS_600348] will be required for all females of child -bearing 
potential. Participants who become pregnant will be discon tinued 
from the study. Also, participants who during the study develop and 
express the intention to become pregnant within the timespan of the 
study will be discontinued.  
7. HbA1c ≥ 7.5% and ≤ 12% at screening  
8. Has current glucagon product to treat severe hypoglycemia 
(injectable or nasal) at home ( will provide prescription if they do not 
have one ) 
9. Be willing to exercise for [ADDRESS_600349] once per week 
during the main phase of the study  
10. Has the ability to read and understand written Eng lish. 
11. Investigator believes that the participant has the capacity such that 
they can provide informed consent and successfully and safely 
operate all study devices and is capable of adhering to the protocol  
and completing the study  
 
Exclusion  Criteria  
1. Prior use of Tandem t:slim X2 insulin pump with Control -IQ 
technolog y 
2. Two or more epi[INVESTIGATOR_116651] (needing assistance) 
in the past [ADDRESS_600350] 6 months  
4. History of drug abuse (def ined as any illicit drug use) or history of 
alcohol abuse prior to screening or unwillingness to agree to abstain 
from illicit drugs throughout the study.  
5. History of significant heart  disease,  lung disease , liver disease, 
chronic kidney disease, or other systemic disease  determined by 
[CONTACT_66698], or make required exercise 
unsafe  
6. History of significant vision , hearing , or dexterity  problems  that will 
impair use of the closed loop system  
7. Use of glucocorticoids, beta blockers , sulfonylureas , meglitinides  or 
other medications specifically listed  in section 8.[ADDRESS_600351], or other 
adjuvant medication specifically listed in section 8.3 of the protocol,  
or starting a new glucose lowering agent during the trial.  
9. Unstable dose of any medication used for weight loss, as listed in 
section 8.3 of the protocol, or starting a new medication for weight 
loss during the trial.  
10. Abnormal screening electrocardiogram consistent with increased risk  
during exercise, such as arrhythmia, ischemia, or prolonged QTc 
interval (>450 ms)  
11. History of hemodialysis  
12. History of adrenal insufficiency  
13. Uncontrolled  hypo - or hyperthyroidism  
14. Significant diabetes related complications, based on investigator 
assessment  
15. Immediate family member (spouse, biological or legal guardian, 
child, sibling, parent) who is an investigative site personnel directly 
affiliated with this study or who is an employee of Tandem Diabetes 
Care, Inc . 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.[ADDRESS_600352] 24 completing the trial  Treatment Groups  All participants will use the study -assigned Control -IQ pump in closed -
loop mode.  Participant Duration  ~8-12 weeks, depending on duration of run -in phase  Study Duration (planned)  ~[ADDRESS_600353] participant visit  Protocol Overview/Synopsis  After consent is signed, eligibility will be assessed.  Eligible participants 
not currently using a Dexcom G6 CGM  or using a Dexcom G6 CGM  with  
<85% of possible glucose values  captured during the 14 days prior to 
enrollment  will initiate a  CGM  run-in phas e of 2-4 weeks. Participants 
who skip or successfully complete the CGM run-in will be trained on use 
of the study pump in open -loop mode and will initiate a pump run -in 
phase of 2 -4 weeks that will include insulin therapy adjustment to 
optimize open -loop g lycemic control.  
  
Participants who successfully complete the open -loop pump run -in will be 
trained on use of the study pump in closed -loop mode  and will use the 
study system (pump and CGM) in closed -loop mode for [ADDRESS_600354] once per 
week.  
 
Questionnaires will be given  at the screening visit  after consent ; before 
starting closed -loop use ( Contr ol-IQ Phase) ; and after 6 weeks of closed -
loop use . Semi -structured interviews will be performed at the end of the 
study to better determine the experience of using the study device  
 
Study Safety Plan :  
Participants will be given a blood glucose and ketone  meter to use 
throughout the study,  and will be trained on their use by [CONTACT_3436]. 
BGM readings will be performed in  accordance with the study safety plan 
and per CGM manufacturer instructions. Ketone  readings will be 
performed per the study safety p lan. 
Site investigators may adjust insulin delivery profile settings as needed 
throughout the study in accordance with their clinical practice.   
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 13 OF 58  Figure 1: Schematic of Study Design 
Screening/Enrollment •Eligibility assessment and informed consent •Device download and adherence assessment for current CGM user  
CGM Placement/Training 
2-4 Week Run-In with home use of study CGM  and 4 weeks Pump Use (pump-naïve participants) 
Tandem pump start and Open-Loop mode training 
 
Eligible to  Skip CGM Run-In*? 
No 
Yes 
* Current use of Dexcom G6 CGM with at least 85% of possible readings captured during the   14 days prior to enrollment 
6 Weeks - End of Study 
6-Week home use of Control-IQ in Closed-Loop mode and 4 weeks Pump Use (pump-naïve participants) 
Phone Contact: [CONTACT_2006] 3; Weeks 1, 4 Clinic Visit: Week 2 
2-4 Week Run-In with home use of pump in Open-Loop mode 
Run-in Review – Reassess Eligibility 
Run-in Review – Reassess Eligibility 
Control-IQ training and Closed-Loop initiation 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 14 OF 58 Table 1: Schedule of Study Visits and Procedures 
[ADDRESS_600355] study staff after each exercise challenge to review AE’s and diabetes management around exercise.  Screen -
ing Visit  CGM  
Run-in 
Visit  (may 
be 
repeated 
after 2 
weeks)  Pump 
Training 
Visit and 
Settings 
Optimization 
(may be 
repeated 
after 2 
weeks)  Control -
IQ Closed -
Loop 
Training 
Visit  Control -IQ Closed -Loop Use    2-4 weeks  2-4 weeks   3d 1w 2w 4w 6w +3d UV Exercise3 Visit (V) or Contact (C)  V V V V C C V C V C V/
C C Informed Consent  X            Eligibility Assessment  X            Medical history/  
physical exam  X            Height, weight, 
blood  pressure  and pulse  X   X2     X2    HbAlc (POC or local 
lab) X            Central Lab: C-peptide 
and Glucose ; HbA1c  X            ECG  X            Pregnancy test  (females 
of child -bearing 
potential)  X   X         Questionnaires /Surveys  X  X X     X    Semi -structured 
interview          X1    Assessment of CGM use  X X           Study system training   X X X       X  AE Assessment   X X X X X X X X X X X Upload device data 
from  home      X X  X   X  Download  device data 
at clinic visit   X X X   X  X  X  
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 15 OF 58 Chapter 1: Background Information [ADDRESS_600356] diabetes, with type 2 diabetes accounting 3 for approximately 90% to 95% of cases. In the last 20 years, the number of adults diagnosed with 4 diabetes has more than doubled as the American population has aged and become more overweight 5 or obese. Diabetes is the 7th leading cause of death in the [LOCATION_002] (and may be 6 underreported). 7 Insulin pump use in individuals with type 2 diabetes is relatively low. However, there is an 8 increasing uptake of insulin pump use in this population. The benefits of insulin pump use with 9 Automated Insulin Dosing (AID) technology in individuals with type 2 diabetes has not been well 10 established in clinical trials, although long term follow-up of real-world data has shown AID use 11 with Control-IQ technology can show significant glycemic benefits in this population, whether 12 transitioning from multiple daily injections (MDI) or prior pump use. Retrospective analysis of 13 134 prior pump users with type 2 diabetes who purchased a new Tandem insulin pump with 14 Control-IQ technology showed time in range was 76% (IQR 69-82%) and time below range was 15 0.5% (IQR 0.2-1.0%) at 180 days out. For 173 participants transitioning from MDI, use of Control-16 IQ technology resulted in time of range of 74% (IQR 63-84%) and time below range 0.3% (IQR 17 0.1-0.6%) at 180 days of use (1). Additionally, retrospective analysis of real-world use out to one 18 year in 378 individuals with type 2 diabetes who software updated from Basal-IQ technology to 19 Control-IQ technology showed significant improvements in time in range 70-180 mg/dL (69% at 20 baseline, 78% at one year) (2). 21  22 1.2 Device Background 23 The t:slim X2 insulin pump with Control-IQ technology is an advanced hybrid closed-loop (HCL) 24 system, developed and manufactured by [CONTACT_3438], Inc. and cleared in the U.S. by 25 the FDA for individuals with type 1 diabetes. Control-IQ is integrated with the Dexcom G6 26 continuous glucose monitor (CGM) and uses CGM values to predict glucose values 30 minutes in 27 the future. Based on the predicted glucose, Control-IQ modulates basal insulin delivery, and 28 delivers automated correction boluses to mitigate impending hyperglycemia. The current Control-29 IQ system is FDA approved down to age 6 years old for individuals with type 1 diabetes, and has 30 been found to improve time in range (70-180 mg/dL) and decrease both time <70 mg/dL and time 31 >180 mg/dL (3,4). There are over 150,000 users of the system since it became commercially 32 available in 2020.  A recent evaluation of real-world use of the system in 9,451 users age ≥[ADDRESS_600357] 12 months of system use found results comparable to those found in the randomized 34 trials (2).  35  36 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 16 OF 58  37 Figure 2. t:slim X2 with Control-IQ and Dexcom G6 system [ADDRESS_600358] usability improvements and other 40 enhancements intended to further reduce risk. The Control-IQ 1.5 algorithm also removes the 3 41 units/hr basal clippi[INVESTIGATOR_007], allowing the pump to deliver programmed user profile basal rates above 3 42 units/hr. This has the potential to further improve outcomes in individuals with type 2 diabetes 43 who are often using basal rates at or above this threshold. 44 1.3 Rationale 45 The objective of this single-arm, prospective study is to assess safety and explore glycemic 46 outcomes associated with use of the Control-IQ system in adults with type 2 diabetes to provide 47 data to design a subsequent larger study.  48 1.4 Potential Risks and Benefits of the Investigational Device 49 Risks and benefits are detailed below. Loss of confidentiality is a potential risk; however, data are 50 handled securely to minimize this risk. Hypoglycemia and hyperglycemia and ketone formation 51 are always a risk in participants with type 2 diabetes and insulin treatment, and participants will 52 be monitored for this. 53 1.4.1 Known Potential Risks 54 [IP_ADDRESS] Potential Risks and Benefits of the CLC System 55 Even though the study system has been tested prior to this study, there is still a risk that parts of 56 the system may not function properly. The following are possible reasons the system may deliver 57 too much insulin or incorrectly stop insulin delivery: 58 • CGM sensor reads higher or lower than the actual glucose level which increases risk for 59 hypoglycemia and hyperglycemia with automated insulin delivery system; 60 • Device malfunctions that could produce a suspension of insulin delivery or over delivery of 61 insulin. 62 [IP_ADDRESS] Risk of Hypoglycemia [ADDRESS_600359] as 66 at home, there is the possibility of fainting or seizures (convulsions) and that for a few days the 67 

JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 17 OF 58 participant may not be as aware of symptoms of hypoglycemia. A CGM functioning poorly and 68 significantly over-reading glucose values could lead to inappropriate insulin delivery. 69 [IP_ADDRESS] Risk of Hyperglycemia 70 Hyperglycemia and ketonemia could occur if insulin delivery is attenuated or suspended for an 71 extended period or if the pump or infusion set is not working properly. Although less common in 72 individuals with type 2 diabetes than in those with type 1 diabetes, DKA can still occur. Extreme 73 levels of hyperglycemia and dehydration can lead to hyperosmolar hyperglycemic syndrome 74 (HHS). A CGM functioning poorly and significantly under-reading glucose values could lead to [ADDRESS_600360] strips, to use to carefully monitor for 77 hyperglycemia and ketones and be given instructions on how to mitigate hyperglycemia and 78 ketosis should it occur.  79 [IP_ADDRESS] Fingerstick Risks 80 About 1 drop of blood will be removed by [CONTACT_468507] 81 Hemoglobin A1c (HbA1c). This is a standard method used to obtain blood for routine hospi[INVESTIGATOR_307] [ADDRESS_600361] for several weeks. The risk 84 of local infection is less than 1 in 1000. This should not be a significant contributor to risks in this 85 study as fingersticks are part of the usual care for people with diabetes. 86 [IP_ADDRESS] Venipuncture Risks 87 A hollow needle/plastic tube may be placed in the arm for taking blood samples. Blood draws can 88 cause some common reactions like pain, bruising, or redness at the sampling site. Less common 89 reactions include bleeding from the sampling site, formation of a small blood clot or swelling of 90 the vein and surrounding tissues, and fainting. 91 [IP_ADDRESS] Subcutaneous Catheter Risks 92 Whenever the skin is broken there is the possibility of bleeding and bruising. The CGM sensor 93 and pump infusion sets are inserted under the skin. It is possible that any part that is inserted 94 under the skin may cause an infection, which could produce swelling, redness, and pain. These 95 occur very infrequently, but if an infection were to occur, oral and/or topi[INVESTIGATOR_3405] [ADDRESS_600362] a small portion of the sensor probe under 100 the skin that may cause redness, swelling or pain at the insertion site. The participant will be 101 instructed to notify the site immediately if this occurs. 102 [IP_ADDRESS] Risk of Exercise 103 Exercise may lead to injury, hypoglycemia or hyperglycemia, or significant events, such as 104 myocardial infarction or other significant cardiac event. Subjects will be instructed on how to 105 prepare for exercise by [CONTACT_464], and intended use of the exercise activity feature. All subjects 106 will undergo a screening ECG to assure exercise can be completed safely. 107 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 18 OF 58 [IP_ADDRESS] Risk of Device Reuse 108 All devices will be used by a single study participant only. There will be no device reuse. 109 [IP_ADDRESS] Questionnaires and Semi-Structured Interviews [ADDRESS_600363] been 115 uncommon. 116 [IP_ADDRESS] Other Risks 117 Some participants may develop skin irritation or allergic reactions to the adhesives used to secure 118 the CGM, or from tape to secure the insulin infusion sets for the continuous subcutaneous insulin 119 infusion. If these reactions occur, different adhesives or “under-tapi[INVESTIGATOR_007]” (such as with IV 3000, 120 Tegaderm, etc.) will be tried, sites will be rotated frequently, and a mild topi[INVESTIGATOR_3406] 121 other medication may be required.  122 Data downloaded from the CGM, pump, and the home glucose and ketone meter will be collected 123 for the study as measures of diabetes self-management behaviors. Downloaded data from the 124 participant’s personal CGM or pump (if any) will include data from prior to the date of the 125 screening visit. Some people may be uncomfortable with the researchers' having such detailed 126 information about their daily diabetes habits. 127 1.4.2 Known Potential Benefits 128 Participants may experience a significant improvement in glucose control. Hypoglycemia is the 129 number one fear of many individuals taking insulin and this fear often prevents optimal glycemic 130 control. Hyperglycemia will likely be reduced as well.  131 In addition, users of insulin pumps often take less insulin than users of basal/bolus injection [ADDRESS_600364] benefit to individual subjects 139 based on the following: (1) individuals with diabetes experience mild hypoglycemia and 140 hyperglycemia frequently as a consequence of the disease and its management, (2) the study 141 intervention involves periodic automated insulin dosing that may reduce the likelihood of 142 hypoglycemia, and periodic automated attenuation of insulin delivery that may reduce the 143 likelihood of hyperglycemia, (3) if any, hypo and/or hyperglycemia occur, mitigations are in place, [ADDRESS_600365] been tested in prior studies using the investigational device system in the home setting, 145 that limit the likelihood of excessive insulin dosing or prolonged withdrawal of insulin, and (4) [ADDRESS_600366] their origin in the Declaration of Helsinki, with the 151 protocol described herein, and with the standards of Good Clinical Practice (GCP). [ADDRESS_600367] that the closed loop system is investigational in the population under study.  156 Therefore, an investigational device exemption (IDE) from the U.S. Food and Drug 157 Administration (FDA) is required to conduct the study. 158 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 20 OF 58 Chapter 2: Study Enrollment and Screening [ADDRESS_600368] signed consent and 163 started the screening process may be permitted to continue into the trial, if eligible, even if the 164 completion goal has been reached. 165 Study participants will be recruited from ~[ADDRESS_600369] to gender, race, or ethnicity. Each site will be asked 167 to contribute ~10 participants (5 basal only / 5 MDI) toward the overall recruitment goal. 168 2.1.1 Informed Consent and Authorization Procedures 169 Potential eligibility may be assessed as part of a routine-care examination.  Before completing 170 any procedures or collecting any data that are not part of usual care, documented informed 171 consent will be obtained. 172 Once a potential study participant has been identified, the study protocol will be discussed with 173 the potential study participant by [CONTACT_464].  The potential study participant will be given the 174 Informed Consent Form to read.  Potential study participants will be encouraged to discuss the 175 study with family members and their personal physicians(s) before deciding whether to 176 participate in the study. If the potential study participant is interested in the study, the 177 investigator will schedule a virtual or in-person visit to discuss study, and if the potential study 178 participant agrees to participate, the Informed Consent Form will be electronically signed 179 through the JCHR website.  A copy of the electronically signed consent form can be printed by 180 the participant and another copy will be printed by [CONTACT_468508]’s study [ADDRESS_600370]. The site shall print a copy of the signed consent for the participant any time at the 182 participant’s request, at no cost, and without undue delay.  183 As part of the informed consent process, each participant will be asked to sign an authorization 184 for release of personal information. This will be done electronically as part of the consent 185 process. The investigator, or his or her designee, will review the study-specific information that 186 will be collected and to whom that information will be disclosed.  After speaking with the 187 participant, questions will be answered about the details regarding authorization. 188 A participant is considered enrolled when the informed consent form has been electronically 189 signed by [CONTACT_128804], and HIPAA authorization has been provided. 190 This process shall be document in the study records at each site (e.g., consent process note).  [ADDRESS_600371] meet all of the following inclusion criteria in order to be eligible to participate 193 in the study. 194 1. Age ≥[ADDRESS_600372] 3 months, to include A) basal insulin only, or B) 198 MDI, to include CSII (including use of AID systems other than Tandem Control-IQ) 199 4. Total daily insulin dose ≤200 units/day 200 5. Willing to use only aspart (novolog) or lispro (humalog) insulin with the study pump, [ADDRESS_600373] will be required for all females of child-bearing 207 potential. Participants who become pregnant will be discontinued from the study. Also, 208 participants who during the study develop and express the intention to become pregnant 209 within the timespan of the study will be discontinued. 210 7. HbA1c ≥ 7.5% and ≤ 12% at screening [ADDRESS_600374] to treat severe hypoglycemia (injectable or nasal) at home 212 (will provide prescription if they do not have one) [ADDRESS_600375] once per week during the main 214 phase of the study 215 10. Has the ability to read and understand written English 216 11. Investigator believes that the participant has capacity such that they can provide informed 217 consent and can successfully and safely operate all study devices and is capable of 218 adhering to the protocol and completing the study. 219 2.3 Participant Exclusion Criteria 220 Individuals meeting any of the following exclusion criteria at baseline will be excluded from 221 study participation. 222 1. Prior use of Tandem t:slim X2 insulin pump with Control-IQ technology 223 2. Two or more epi[INVESTIGATOR_116651] (needing assistance) in the past [ADDRESS_600376] 6 months 225 4. History of drug abuse (defined as any illicit drug use) or history of alcohol abuse prior to [ADDRESS_600377], or other adjuvant medication 236 specifically listed in section 8.3 of the protocol, or starting a new glucose lowering agent 237 during the trial. 238 9. Unstable dose of any medication used for weight loss, as listed in section 8.3 of the 239 protocol, or starting a new medication for weight loss during the trial. 240 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 22 OF 58 10. Abnormal screening electrocardiogram consistent with increased risk during exercise, 241 such as  arrhythmia, ischemia, or prolonged QTc interval (>450 ms) 242 11. History of hemodialysis  243 12. History of adrenal insufficiency 244 13. Uncontrolled hypo- or hyperthyroidism 245 14. Significant diabetes related complications, based on investigator assessment 246 15. Immediate family member (spouse, biological or legal guardian, child, sibling, parent) [ADDRESS_600378] physical exam (including vital signs and height and weight measurements) will be 257 performed by [CONTACT_3437] (a physician, fellow, nurse practitioner or a 258 physician assistant). 259 The following procedures will be performed/data collected/eligibility criteria checked and 260 documented: 261 • Inclusion and exclusion criteria assessed 262 • Demographics (date of birth, sex, race and ethnicity) 263 • Contact [CONTACT_3031] (retained at the site and not entered into study database) 264 • Medical history, including existing comorbidities deemed clinically relevant (e.g. 265 retinopathy, nephropathy, neuropathy, history of cardiovascular events); in addition, details 266 specific to type 2 diabetes, including age at diagnosis, duration of disease, previous therapy, 267 and frequency of severe hypoglycemia will be collected 268 • Concomitant medications 269 • Physical examination to include: 270  Weight, height 271  Vital signs including measurement of blood pressure and pulse 272 • An electrocardiogram (ECG) will be administered and read locally by [CONTACT_43073] [ADDRESS_600379] to the exercise component 274 of the study 275 • Fingerstick or blood draw for point-of-care or local laboratory determination of baseline 276 HbA1c level and any local laboratory testing required for eligibility assessment 277 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 23 OF 58 • Blood draw for Central Lab determination of HbA1c and C-peptide with concurrent glucose 278 level 279 • Urine or serum pregnancy test for all women who have reached menarche and are 280 premenopausal and are not surgically sterile 281 • Barrier methods, oral contraceptives, and implantable and/or IUD-type contraceptives are 282 examples of methods that constitute acceptable methods of contraception for females of 283 child-bearing potential, and will be discussed with all such females who are not 284 postmenopausal or surgically sterile. 285 • Females are considered premenopausal per investigator discretion, typi[INVESTIGATOR_468504] [ADDRESS_600380] menses. 287 • Participants will complete a set of baseline questionnaires, described in section 6.[ADDRESS_600381] approximately 1-2 hours. 289 2.5 Screen Failures 290 Individuals who do not initially meet study eligibility requirements may be rescreened once at a 291 later date per investigator discretion. 292  293  294 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 24 OF 58 Chapter 3: CGM and Pump Run-in Phases [ADDRESS_600382] begin within 7 days of completion of the Screening visit. The purpose of this 297 CGM run-in phase is to 1) assess compliance with study procedures and 2) to introduce the study [ADDRESS_600383] 85% of possible CGM readings [ADDRESS_600384] <85% of possible 302 CGM readings in the 14 days prior to the time of enrollment, will be required to participate in the 303 CGM Run-in phase. 304 Participants will receive training on the study CGM as detailed below. This will be an unblinded 305 use of the study CGM.  306 3.2 Initiation of CGM 307 During an in-clinic visit that may coincide with the Screening visit, study CGM supplies will be 308 provided and the participant will be instructed to use the study CGM on a daily basis. Participants 309 using a personal CGM prior to the study will discontinue the personal CGM beginning in this 310 period. 311 3.2.1 CGM Training 312 CGM training will be provided by a qualified trainer to participants not currently using a personal 313 CGM identical to the study CGM as to how to use it in real-time to make management decisions 314 and how to review the data after an upload for retrospective review. CGM training will include: 315 • Instruction on how to insert the sensor and transmitter, including observation/supervision 316 of placement of a sensor 317 • Instruction on how to calibrate the CGM unit, if needed 318 • Guidance on accessing the CGM trace, either through a manufacturer-provided software 319 app or via a study-provided CGM receiver unit, or via a personal insulin pump if 320 participants use a pump that integrates with the study CGM 321 • Participants will be asked to perform fingerstick blood glucose measurements in 322 accordance with the labeling of the study CGM device 323 A copy of the study CGM user’s guide will be provided to the participant. [ADDRESS_600385]-party components for this purpose. The t:connect mobile app from Tandem Diabetes Care [ADDRESS_600386], 329 that the participant is familiar with the functions/features/tasks addressed during the training. 330 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 25 OF 58 3.3 Blood Glucose and Blood Ketone Testing 331 Participants will receive supplies for blood glucose and blook ketone testing. 332 • Blood glucose testing [ADDRESS_600387] strips, and any 334 software/hardware needed to download meter data . 335 o All study blood glucose meters will be QC tested with control solution if available prior to 336 dispensation.  A tested meter will not be used in a study if it does not read within the target 337 range at each concentration per manufacturer labeling.   338 o Participants will be reminded to use the study blood glucose meter for all fingerstick BGs 339 during the study. 340 o Participants will be given guidelines for treatment of low or high blood glucose. 341 • Blood ketone testing [ADDRESS_600388] strips, and any 343 software/hardware needed to download meter data. 344 o All study blood ketone meters will be QC tested with control solution if available prior to 345 dispensation.  A tested meter will not be used in a study if it does not read within the target 346 range at each concentration per manufacturer labeling.   347 o Participants will be reminded to use the study blood ketone meters per the study 348 hyperglycemia safety plan 349 o Participants will be given guidelines for treatment of positive ketone readings. 350 • Participants will be required to have glucagon at home. Participants who currently do not have [ADDRESS_600389] care (either emergency kit for 352 injections or nasal glucagon per investigator discretion). [ADDRESS_600390] the participant with any CGM use issues. Procedures 357 will include downloading of the study CGM data and the following: 358 • Assessment of compliance with the use of CGM to obtain at least 85% of possible CGM 359 valued during the run-in period 360 • Assessment of skin reaction in areas where a CGM sensor was worn or other safety issues 361 associated with CGM use 362 • Assessment of eligibility to continue to the pump run-in phase of the study 363 Participants who fail to meet the minimum CGM use requirement, or who the investigator believes 364 may benefit from an extension of the CGM run-in period, may at the investigator’s discretion be 365 allowed to continue CGM run-in for a second ~2-week period. These participants will have another [ADDRESS_600391] begin either on the same day as the final CGM run-in review visit (for participants 372 participating in CGM run-in) or within 7 days of completion of the Screening visit (for participants 373 skippi[INVESTIGATOR_468505]-in). The purpose of the Pump Run-in phase is 1) to assess compliance with 374 study procedures and 2) to allow the participant to transition to the study insulin pump, learn how 375 to use it in open-loop mode, and learn infusion set care. 376 Participants will receive training on use of the study pump in open-loop mode as detailed below.  377 3.6 Initiation of the Study Pump 378 During an in-clinic visit, the study pump, associated supplies, and training will be provided to 379 participants and the participant will be instructed to use the pump in open-loop mode in 380 conjunction with the study CGM until the Pump Run-in review visit. 381 3.6.1 Study Pump Training 382 Participants will receive study pump training on use of the pump in open-loop mode by a 383 qualified trainer: 384 • Participants will be fully instructed on the study insulin pump. The trainer will discuss 385 differences from the participant’s personal pump, if applicable, in important aspects such [ADDRESS_600392] and correction boluses and optional additional topi[INVESTIGATOR_1102] 387 such as: infusion site initiation, cartridge/priming procedures, setting up the pump, 388 charging the pump, navigation through menus, bolus procedures including stoppi[INVESTIGATOR_007] a 389 bolus, etc. 390 • Participants will be instructed to change the study insulin pump infusion set at least once 391 every 3 days or per manufacturer guidelines, whichever is shorter. 392 • Participants using bolus insulin doses at enrollment will be trained to use the pump’s bolus 393 calculator. 394 o For subjects who may only bolus one or two meals a day, or use fixed bolus 395 amounts as part of their prior treatment plan, they may continue to do this in the 396 study, but they will be taught to enter the same number of units in the bolus 397 calculator (Simplified Bolus Plan). 398 o Additionally, it is possible during the study some subjects in the basal only group, 399 or using simplified boluses, may realize the need to add boluses or begin using the 400 bolus calculator, respectively. As such, they will be advanced in their bolus strategy 401 per investigator discretion.  402 • The study team will assist the participant in study pump infusion site initiation and will 403 start the participant on the study pump. The study pump will be programmed with the 404 participant’s usual basal rates and pump parameters, if applicable. The participant’s 405 personal pump, if any, will be removed. 406 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 27 OF 58 • The participant will be supervised with the study pump during at least one meal or snack 407 bolus to ensure participant understanding of the pump features. 408 • The participant will be encouraged to review the literature provided with the pump and 409 infusion sets after the training is completed. 410 • The participant will be trained on severe hypoglycemia emergency procedures including 411 removal of the study pump and administration of glucagon. 412 • What to do when exercising while using the system 413 • The participant will be assessed for understanding of the system interface and how to react 414 to safety/alert messages. 415 • To prevent insulin stacking from basal insulin that is on board, participants using basal 416 insulin at baseline will be instructed, and supervised by [CONTACT_464], to set a temp basal rate 417 to 0% that will end [ADDRESS_600393] this procedure 419 per their usual clinical practice, and may customize this plan based on the type of basal 420 insulin used (for example, insulin degludec with a longer half-life may require a basal rate 421 of 50% for a second day). 422 A copy of the study pump user’s guide will be provided to the participant. 423 3.6.2 Initiation of Pump by [CONTACT_3427] 424 For MDI participants being started on the study pump, an initial basal insulin profile will be 425 customized on a per-participant basis. Total daily insulin dose will be reduced by [CONTACT_3450] 426 20% as a general rule, with a recommended method outlined in a separate procedures’ manual. 427 Further adjustments to total daily dose (TDD) and intraday basal rate profile may be made during 428 the Pump run-in period. 429 Participants will complete training on the study pump as described above, with additional 430 emphasis on topi[INVESTIGATOR_468506], such as infusion site initiation, cartridge/priming [ADDRESS_600394] the participant in study pump infusion site initiation and will start the 434 participant on the study pump. The study pump will be programmed with the participant’s insulin [ADDRESS_600395], that the participant is familiar with the functions/features/tasks addressed during the 443 training. 444 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 28 OF 58 Participants will be provided Hyperglycemia and Hypoglycemia Guidelines during closed-loop 445 use (section 5.2) for when their glucose levels are >300 mg/dL for more than 60 minutes or >400 446 mg/dL at any time or <70 mg/dL. [ADDRESS_600396] the participant with any system use issues. Procedures 454 will include downloading of the study pump and CGM data and the following: 455 • Assessment of compliance with use of the pump, including avoidance of closed-loop mode, 456 timely cartridge and infusion set changes, and announcement of meal boluses throughout 457 the run-in period 458 • Review of insulin therapy settings and adjustments to pump settings (basal rates, correction 459 factor, insulin-to-carbohydrate ratio, etc.) or injection strategies in response to major trends 460 observed in the CGM data 461 • Assessment of eligibility to continue to the main closed-loop phase of the study 462 Participants who the investigator believes may benefit from an extension of the Pump Run-in 463 period may continue Pump Run-in for a second ~2-week period. These participants will have 464 another follow-up visit approximately 14 days after the prior visit for a reassessment using the 465 same procedures as described above. 466 Participants who do not meet system use compliance requirements after a second period of Pump 467 Run-in or otherwise fail to meet study eligibility requirements will be withdrawn from the study. 468 3.9 Optimization of Insulin Therapy 469 Data will be obtained from CGM and/or pump downloads at the CGM and pump run-in review 470 visit(s). Adjustments to pump settings (basal rates, correction factor, insulin-to-carbohydrate ratio, 471 etc.) or injection strategies will be made in response to major trends observed in the CGM data, 472 with flexibility for clinicians to adhere to guidelines and practices established at each individual 473 practice rather than a fixed set of heuristics for all clinical centers. 474  475 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 29 OF 58 Chapter 4: Control-IQ (Closed-Loop) Phase 476 4.1 Control-IQ Phase Overview 477 Initiation of the Control-IQ study phase, involving use of the study pump in closed-loop mode for 478 6 weeks, will coincide with the final Pump Run-in follow-up clinic visit described above. 479 During the Control-IQ phase, visits and contacts will be scheduled as outlined in Table 2 below: 480 Table 2: Control-IQ Phase Visit and Phone Contact [CONTACT_263219] 481 Target Day/Week  Contact [CONTACT_39764]1 Target/ Allowable Window  
(around Target Day/Week)  3 days  P ± 2 days  1 week  P ± 2 days  2 weeks  V ± 4 days  3 weeks  P ± 4 days 6 weeks  V ± [ADDRESS_600397] -study  P ± [ADDRESS_600398] Types are defined as Clinic Visit (V) or Phone call (P); Phone calls may be replaced by [CONTACT_468509] 482 Visits at investigator discretion 483 4.1.1 Study Pump Training  484 Participants will receive instruction from a qualified trainer on use of the study pump in closed-loop 485 mode, to include the following:  486 • How to turn on and off Control-IQ technology 487 • How to understand when Control-IQ is increasing or decreasing basal rates 488 • How to administer a meal or correction boluses during closed-loop system use 489 • What to do when exercising while using the system in closed-loop mode 490 • How to enable the sleep function and set the sleep schedule 491 • The participant will be assessed for understanding of the system interface and how to react 492 to safety/alert messages. [ADDRESS_600399], that the participant is familiar with the functions/features/tasks addressed during the 495 training. 496 4.1.2 System Use Guidelines 497 The participant will be instructed to use the system in closed-loop mode except if insulin is 498 delivered by [CONTACT_3451] (e.g. injection of subcutaneous insulin via 499 syringe in the event of infusion site failure). If insulin is delivered by [CONTACT_418091] [ADDRESS_600400] study staff in case of illness with an elevated 502 temperature >101.5 degrees Fahrenheit (38.6 degrees Celsius), other periods of significant illness, [ADDRESS_600401] is required and will make 512 arrangements for the contacts.  If the participant cannot be reached, the participant’s other contact [ADDRESS_600402].  Participants who are not compliant with 514 the arranged contacts on two separate occasions may be discontinued at the discretion of the 515 investigator.  516 4.1.3 Home Use of the Study System 517 After training on closed-loop aspects of the study system has been completed, participants will 518 proceed with home use (meaning free-living use at school, home, etc.) of the study pump. [ADDRESS_600403] once per week for a minimum of 30 minutes of exercise.  521 Follow up visits will occur per the visit listing described below. If necessary, visits should be 522 completed out-of-window rather than missed. A visit is not considered missed until the next 523 visit/phone window opens.  524 The goal will be for all participants to complete all scheduled visits.  However, participants who 525 (because of unforeseen circumstances or due to changes in contact [CONTACT_468510] 526 needed during the evolving COVID-19 pandemic) are unable or unwilling to return for all 527 follow-up visits will be permitted to return for key visits only as an alternative to withdrawal 528 from the study.  When a participant is placed into this status, missed visits will not be recorded as 529 protocol deviations (since they would not be recorded as protocol deviations if the participant 530 was dropped from the study). 531 Additional office visits may occur as needed. 532 Study Specific Guidance for the Exercise Challenges 533 Study staff will review with participants that for each weekly exercise challenge, they will be 534 required to: [ADDRESS_600404] 539 and limit hypoglycemia. 540 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 31 OF 58 4. Participants will write down the type of exercise performed, as well as the start and stop time 541 of each exercise session on the study logbook, as this may not correlate exactly with exercise 542 activity use on the pump. 543 5. Participants will be instructed that they may stop the exercise challenges at any point for 544 injury or development of new symptoms (development of chest pain/pressure, feeling unwell, 545 development of hypoglycemic symptoms, undue shortness of breath, signs of poor perfusion 546 (leg pain/claudication), or for any other reason. 547 6. Participants will then notify the site within 24 hours after completion of each exercise 548 challenge. The site staff will review for adverse events or new symptoms (See section 4.1.11) [ADDRESS_600405] to remind the participant of the required follow-up and encourage completion of the 553 remaining exercise challenges. If a participant has to reschedule their exercise sessions, or 554 postpone them for any reason (for example, the gym where they walk on a treadmill is too 555 crowded and they did not want to enter to limit exposures due to COVID-19), they will be [ADDRESS_600406] 565 Study staff will perform a phone call with the participant within 3 (±2) days following initiation 566 of closed-loop system use. 567 The following will occur: 568 • Assessment of compliance with study device use by [CONTACT_66706] 569 • Assessment of adverse events, adverse device effects, and device issues 570 • Study staff will answer any questions related to device use and follow the procedure for [ADDRESS_600407]  573 Study staff will perform a phone call with the participant within 7 (±2) days following Initiation 574 of the Control-IQ study phase. 575 The following will occur: 576 • Assessment of compliance with study device use by [CONTACT_66706] 577 • Assessment of adverse events, adverse device effects, and device issues 578 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 32 OF 58 • Study staff will answer any questions related to device use and follow the procedure for [ADDRESS_600408] a follow-up visit 14 (±4) days from the date of initiation of closed-loop 582 system use. 583 The participant will be offered review training to address any questions on the use of the study 584 device including meal bolus strategies and strategies related to pump use and exercise. 585 The following will occur: 586 • Assessment of compliance with study device use by [CONTACT_66706] 587 • Assessment of adverse events, adverse device effects, and device issues 588 • Study staff will answer any questions related to device use and follow the procedure for 589 insulin pump optimization described above if necessary. 590 • Download of device data (study pump, study CGM, study BG meter) as available [ADDRESS_600409]  592 Study staff will perform a phone call with the participant within 28 (±4) days from the date of 593 initiation of closed-loop system use. 594 The following will occur: 595 • Assessment of compliance with study device use by [CONTACT_66706] 596 • Assessment of adverse events, adverse device effects, and device issues 597 • Study staff will answer any questions related to device use and follow the procedure for [ADDRESS_600410] a final visit within 42 (±4) days from the date of initiation of closed-loop 601 system use, during which the following will occur: 602 • Completion of questionnaires  603 • Collection of exercise logbook 604 • Weight and height measurements will be repeated 605 • Assessment of adverse events, adverse device effects, and device issues 606 • Download of device data (study pump, study CGM, study BG meter) as available 607 • Study staff will supervise the participant’s transition back to their prior therapy [ADDRESS_600411]’s baseline therapy doses, noting changes in [ADDRESS_600412] match the 612 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 33 OF 58 current daily insulin requirements from CSII use, typi[INVESTIGATOR_897] = (total daily dose + 613 20%)/2, with further modification as per clinical site usual practice.  [ADDRESS_600413]-study phone call 3 (±1) days after the date of their 6-Week visit 621 and transition back to their prior insulin therapy, during which the following will occur: 622 • Check on transition back to usual home diabetes care 623 • Assessment of adverse events [ADDRESS_600414] study staff within 24 hours of completing each exercise 626 challenge, per guidance in section 4.1.3. The follow up call will review: 627 • The start and stop time, as well as the type of exercise performed. 628 • Assessment of adverse events 629 • Documentation of any safety concerns if future exercise challenges are cancelled. 630 4.2 Early Termination Visit (If Applicable) [ADDRESS_600415] unscheduled visits during the study period if required for additional device 635 training or other unanticipated needs per the study investigator discretion. 636 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 34 OF 58 Chapter 5: Study Devices 637 5.1 Description of the Investigational Device 638 5.1.1 Insulin Pump 639 The study system will include the Tandem t:slim X2 insulin pump (K201214, Tandem Diabetes 640 Care, San Diego, CA) using firmware version 1.5. [ADDRESS_600416] once every 10 days or as per manufacturer instructions. 644 5.1.3 Blood Glucose Meter and Strips 645 Blood glucose levels will be measured using the study-assigned blood glucose meter 646 (glucometer) and the CGM device will be calibrated if needed using the study glucometer and 647 strips in accordance with the manufacturer’s labeling. (Contour NEXT or Contour NEXT ONE, [ADDRESS_600417], Parsippany, NJ [ZIP_CODE] [LOCATION_003]. 649 5.1.4 Ketone Meter 650 The study blood ketone meter is the Precision Xtra Blood Glucose and Ketone Monitoring 651 System (Abbott Diabetes Care). 652 Blood ketone levels will be measured when needed to evaluate prolonged hyperglycemia. The 653 blood glucose meter component of the Precision Xtra device will not be used. 654 5.1.5 Study Device Accountability Procedures 655 Device accountability procedures will be detailed in the site procedures manual. 656 5.2 Safety Measures 657 5.2.1 CGM Calibration 658 Throughout the study, participants will be instructed to calibrate the study CGM in accordance 659 with manufacturer labelling. 660 5.2.2 Pump Failure 661 The study insulin pump is designed to revert to open-loop delivery of preprogrammed basal 662 insulin levels in the event that CGM data are not available. The pump also includes various 663 alarms and alerts to notify the user when there is a problem with insulin delivery. 664 5.2.3 Hypoglycemia Threshold Alarm and Safety Protocol 665 When using the study device, hypoglycemia low threshold alerts will be set to no lower than 70 666 mg/dL, and if a participant’s CGM reading is <70 mg/dL, subjects will be instructed to treat with 667 ~15 grams of carbohydrate and perform fingerstick testing as necessary per CGM manufacturer 668 instructions. 669 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 35 OF 58 5.2.4 Hyperglycemia Threshold Alarm and Safety Protocol 670 During the course of the study, participants will be permitted to change this setting, but will be 671 instructed to choose a value no greater than 300 mg/dL. 672 During the CGM run-in and open-loop pump wear period, if a participant’s CGM reading is 673 >300 mg/dL for over 2 hours: 674 • Perform a blood glucose meter check. 675 • For bolus insulin users, if the blood glucose is >300 mg/dL, give a correction dose of insulin [ADDRESS_600418] hour. If blood glucose does not decrease by 50 677 mg/dL within [ADDRESS_600419] study staff for further instructions. 678 • For basal insulin users, contact [CONTACT_468511]. 679 During the time period when the closed-loop system is operational and active, if a participant’s 680 CGM reading is >300 mg/dL for over 1 hour or ≥400 mg/dL at any point, or the participant 681 experiences severe symptoms of hyperglycemia (nausea, vomiting, abdominal pain), the 682 participant will be instructed to take the following steps: 683 • Perform a blood glucose meter check. 684 • If the blood glucose is >300 mg/dL, check for blood ketones with the study ketone meter. 685 • If the ketone level is ≥ 0.6 mmol/L (or ≥ 2.5 mmol\L at any time), take correction insulin, 686 change insulin (pump) infusion site and contact [CONTACT_464]. Continue to monitor their 687 glucose and blood ketone levels until they return to normoglycemia and ketones are < 0.6 688 mmol/l. 689  If ketones are <0.6 mmol/l, they will be advised to continue to monitor their glucose 690 until it returns to normoglycemia and to repeat the ketone measurement in 90 minutes 691 if necessary. 692  If glucose fails to correct, or symptoms persist, contact [CONTACT_468512] 693 further instructions, to include giving a correction dose by [CONTACT_17838]. 694 • If correction insulin is administered via insulin syringe, turn Control-IQ off for 695 approximately four hours and until glucose level has returned to <180 mg/dL. 696 • If unable to contacts study staff and the participant is vomiting, go to the Emergency [ADDRESS_600420] occur 701 within 7 weeks (49 days) of initiation of closed-loop system use.702 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 36 OF 58 Chapter 6: Testing Procedures and Questionnaires 703 6.1 Laboratory Testing 704 1. HbA1c: 705 • HbA1c level measured using the DCA2000 or comparable point of care device or local 706 lab at the Screening visit, if no comparable measurement is available from the 2 weeks 707 prior to enrollment 708 • HbA1c level measured at a Central Lab from blood draw performed at Screening visit 709 2. C-peptide/Glucose: 710 • C-peptide with concurrent glucose level measured at a Central Lab from blood draw 711 performed at Screening visit 712 3. Urine Pregnancy: 713 • Performed locally for females of child-bearing potential at Screening and at the Control-714 IQ phase initiation visit.  This will also be done anytime pregnancy is suspected. 715 Local laboratory testing will be performed if needed to screen for exclusionary medical 716 conditions. 717 6.2 Electrocardiogram (ECG) 718 An ECG will be administered using the clinic’s ECG machine and read locally by [CONTACT_941] [ADDRESS_600421] to the exercise component of the study. The printed ECG with the investigator’s [ADDRESS_600422] be saved in the study records (note – making a copy of the 722 ECG once signed preserves the integrity of the read due to the fragility of the printer paper). [ADDRESS_600423] MEASURED/RELE VANT POINTS  ADMINISTRATION 
POINTS  Tandem Study -
Specific Baseline 
Survey  A Tandem -specific 4 -item questionnaire that captures 
information about Healthcare Provider relationships, comfort 
with new technologies for diabetes management, and comfort 
understanding written information . (3 mins ) • Screening Visit  Altarum Consumer 
Engagement (ACE) 
Measure  – 
Commitment 
Subscale  A 6-item questionnaire measur ing commitment to everyday 
health behaviors. Predicts overall health, adherence to medical 
guidance, and success at chronic disease management . (2 mins)  • Screening Visit  
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.[ADDRESS_600424] MEASURED/RELE VANT POINTS  ADMINISTRATION 
POINTS  Tandem Pump 
Training Survey  A Tandem -specific 4 -item questionnaire that captures patient -
reported experience with Tandem pump training, including 
overall satisfaction and time investment. (3 mins)  • Pump Run -In 
Initiation Visit  
• Control -IQ 
Initiation Visit  DAWN Impact of 
Diabetes Profile 
(DIDP)  A 7-item questionnaire providing a valid and reliable measure of 
the perceived impact of diabetes on quality of life, suitable for 
adults with Type 1 or Type 2 diabetes mellitus . (2 mins)  • Screening Visit  
• Control -IQ 
Initiation Visit  
• 6-Week Visit  Diabetes Impact and 
Device Satisfaction 
(DIDS) Scale  A 12-item questionnaire focused on satisfaction related to 
insulin delivery device s (e.g., trust and ease of use)  and diabetes -
related impact on daily life, such as worry around hypoglycemia  
and sleep in terruptions . (3 mins)  • Screening Visit  
• Control -IQ 
Initiation Visit  
• 6-Week Visit  PROMIS Sleep -
Related Impairment 
Questionnaire  An 8 -item questionnaire that measures s leep disturbance and 
sleep -related impairment . (2 mins)  • Screening Visit  
• Control -IQ 
Initiation Visit  
• 6-Week Visit  System Usability 
Scale (SUS)  A 10 -item questionnaire that measures the overall usability of a 
system. It is a valid and reliable measure of the perceived 
usability of a system and is technology -agnostic. (2 mins)  • Control -IQ 
Initiation Visit  
• 6-Week Visit   [ADDRESS_600425] approximately 30 minutes and 732 will be conducted by [CONTACT_468513] a script of open-ended questions to gather feedback and 733 reactions to the closed loop system, the clinical trial, and QoL changes. 734 Interview sessions may be audio- or video-taped and transcribed by a professional transcription 735 service. Otherwise, these recordings will not be shared for any non-study purposes. 736 Transcriptions will use a code for participants, such as “Participant 1”, and will not contain 737 names or other identifiers of participants.738 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 38 OF 58 Chapter 7: Unanticipated Problem, Adverse Event, and Device Issue [ADDRESS_600426] report Unanticipated Problems to the IRB 743 within seven (7) calendar days of recognition. For this protocol, an unanticipated problem is an 744 incident, experience, or outcome that meets all of the following criteria: 745 • Unexpected (in terms of nature, severity, or frequency) given (a) the research procedures 746 that are described in the protocol related documents, such as the IRB-approved research 747 protocol and informed consent document; and (b) the characteristics of the subject 748 population being studied 749 • Related or possibly related to participation in  the research (possibly related means there [ADDRESS_600427] been 751 caused by [CONTACT_3459]) 752 • Suggests that the research places participants or others at a greater risk of harm than was 753 previously known or recognized (including physical, psychological, economic, or social 754 harm) 755 An example of an unanticipated problem in this study would be incidence rates of hypo- or 756 hyperglycemia in the study (T2D) population, related to closed-loop insulin delivery, that are [ADDRESS_600428] be reported to the 762 JCHR IRB within seven (7) calendar days of recognition. The Director of the Human Research 763 Protection Program (HRPP) will report to the appropriate regulatory authorities if the IRB 764 determines that the event indeed meets the criteria of an Unanticipated Problem requiring 765 additional reporting to fulfill the reporting obligations of the HRPP. 766 7.2 Adverse Events 767 7.2.1 Definitions 768 Adverse Event (AE): Any untoward medical occurrence (including laboratory findings) 769 associated with study procedures, the use of a device, biologic, or drug in humans, including any 770 comparator used, whether or not the event is considered related (i.e., irrespective of the 771 relationship between the adverse event and the device(s) under investigation). 772 Serious Adverse Event (SAE): Any untoward medical occurrence that results in any of the 773 following outcomes: 774 • Death. 775 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 39 OF 58 • A life-threatening adverse event; (a non-life-threatening event which, had it been more [ADDRESS_600429] become life-threatening, is not necessarily considered a serious adverse 777 event). 778 • Inpatient hospi[INVESTIGATOR_1081]. 779 • A persistent or significant disability/incapacity or substantial disruption of the ability to [ADDRESS_600430] normal life functions (sight threatening). 781 • A congenital anomaly or birth defect. [ADDRESS_600431] and may require medical and surgical intervention to 785 prevent one of the outcomes listed in this definition. Note: If either the Sponsor or investigator [ADDRESS_600432] (UADE): Any serious adverse effect on health or safety or [ADDRESS_600433], 790 problem, or death was not previously identified in nature, severity, or degree of incidence in the 791 investigational plan or application (including a supplementary plan or application), or any other 792 unanticipated serious problem associated with a device that relates to the rights, safety, or 793 welfare of participants (21 CFR 812.3(s)). [ADDRESS_600434] (ADE): An adverse event related to the use of an investigational medical 795 device. This definition includes adverse events resulting from insufficient or inadequate 796 instructions for use, deployment, implantation, installation, or operation, or any malfunction of 797 the investigational medical device. This definition includes any event resulting from use error or 798 from intentional misuse of the investigational medical device. This includes comparator if the 799 comparator is a medical device. (Note that an Adverse Event Form is to be completed in addition 800 to a Device Deficiency or Issue Form, unless excluded from reporting as defined in section 8.2). 801 Comparator: Medical device, therapy (e.g. active treatment, normal clinical practice), placebo or 802 no treatment, used in the control group in a clinical investigation. (ISO [ZIP_CODE]:2020) 803 Device Complaints and Malfunctions: A device complication or complaint is something that 804 happens to a device or related to device performance, whereas an adverse event happens to a 805 participant.  A device complaint may occur independently from an AE, or along with an AE.  An 806 AE may occur without a device complaint or there may be an AE related to a device complaint.  807 A device malfunction is any failure of a device to meet its performance specifications or 808 otherwise perform as intended.  Performance specifications include all claims made in the 809 labeling for the device.  The intended performance of a device refers to the intended use for 810 which the device is labeled or marketed. (21 CFR 803.3).  Note: for reporting purposes, sites will 811 not be asked to distinguish between device complaints and malfunctions. 812 Use Error: User action or lack of user action while using the medical device (3.34) that leads to a 813 different result than that intended by [CONTACT_3460]. Includes the 814 inability of the user to complete a task. Use errors can result from a mismatch between the 815 characteristics of the user, user interface, task or use environment. Users might be aware or 816 unaware that a use error has occurred. An unexpected physiological response of the patient is not 817 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 40 OF 58 by [CONTACT_3461] a use error. A malfunction of a medical device that causes an unexpected 818 result is not considered a use error. (ISO [ZIP_CODE]:2020) [ADDRESS_600435] medical occurrence that 822 meets one of the following criteria: 823 1. An SAE as defined in section 7.2.1 824 2. An ADE as defined in section 7.2.1, unless excluded from reporting in section 7.3 825 3. An AE as defined in 7.2.1 occurring in association with a study procedure 826 4. An AE as defined in 7.2.1 not related to a device issue which leads to temporary or 827 permanent discontinuation of  a study device 828 5. An AE as defined in 7.2.1 that affects the participant’s ability to complete any study 829 procedures 830 6. An AE as defined in 7.2.1 for which a visit is made to a hospi[INVESTIGATOR_3409]   831 7. Hypoglycemia meeting the definition of reportable hypoglycemia as defined below 832 8. Diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic syndrome (HHS) as defined 833 below; or in the absence of DKA/HHS, hyperglycemia or ketosis event meeting the criteria [ADDRESS_600436] or discontinuation of the study device.  837 Skin reactions from sensor placement are only reportable if severe and/or required treatment. 838 All reportable AEs—whether volunteered by [CONTACT_2299], discovered by [CONTACT_3462] [ADDRESS_600437], or other means—[ADDRESS_600438] or discontinuation of the study 844 device is only reportable as an adverse event when one of the following criteria is met: 845 • a hypoglycemic event occurred meeting the following definition of severe hypoglycemia:  846 the event required assistance of another person due to altered consciousness, and required 847 another person to actively administer carbohydrate, glucagon, or other resuscitative 848 actions.  This means that the participant was impaired cognitively to the point that he/she 849 was unable to treat himself/herself, was unable to verbalize his/ her needs, was 850 incoherent, disoriented, and/or combative, or experienced seizure or loss of 851 consciousness.  These epi[INVESTIGATOR_66683] 852 induce seizure or loss of consciousness.  If glucose measurements are not available 853 during such an event, neurological recovery attributable to the restoration of glucose to 854 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 41 OF 58 normal is considered sufficient evidence that the event was induced by a low glucose 855 concentration. 856 • evaluation or treatment was obtained at a health care provider facility for an acute event 857 involving hypoglycemia, or the participant contact[CONTACT_3464]  858 following the occurrence of an acute event involving hypoglycemia 859 When a severe hypoglycemia event occurs (as defined above), a Hypoglycemia Form should be [ADDRESS_600439] to reporting requirements. When a severe 862 hypoglycemia event occurs during use of a study device, it generally will be considered to be 863 unrelated to the device (per section 7.2.5) if the device functioned as intended and there does not 864 appear to be a flaw in how the device is intended to function. 865 7.2.4 Hyperglycemic/Ketotic Events [ADDRESS_600440] or discontinuation of the study 867 device is only reportable as an adverse event when one of the following criteria is met:   868 • the event involved DKA, as defined by [CONTACT_3467] 869 (DCCT) and described below 870 • the event involved hyperosmolar hyperglycemic syndrome (HHS), as defined by [CONTACT_941] 871 American Diabetes Association and described below 872 • evaluation or treatment was obtained at a health care provider facility for an acute event 873 involving hyperglycemia or ketosis, or the participant contact[CONTACT_3466] 874 guidance on how to manage the hyperglycemia/ketosis 875 Hyperglycemic events are classified as DKA if the following are present: 876 • Symptoms such as polyuria, polydipsia, nausea, or vomiting; 877 • Serum ketones >1.5 mmol/L or large/moderate urine ketones; 878 • Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate (or CO2) <15; and 879 • Treatment provided in a health care facility 880 Hyperglycemic events are classified as HHS if the following are present: 881 • Symptoms such as polyuria, polydipsia, nausea, or vomiting; 882 • Plasma glucose levels are very elevated (typi[INVESTIGATOR_897] > 600 mg/dL); 883 • Plasma effective osmolarity is >320 mOsm/L; 884 • Absence of significant ketones; and 885 • Treatment provided in a health care facility 886 When a hyperglycemia/ketotic event qualifies as an SAE as defined in section 7.2.1 , a 887 Hyperglycemia/DKA Form should be completed in addition to the Adverse Event Form. Events [ADDRESS_600441] to 889 reporting requirements. Hyperglycemia events not meeting criteria for DKA or HHS generally 890 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 42 OF 58 will not be considered as serious adverse events unless one of the SAE criteria in section 7.2.1 is 891 met. 892 When a hyperglycemia/DKA event occurs during use of a study device, it generally will be 893 considered to be unrelated to the device (per section 7.2.5) if the device functioned as intended [ADDRESS_600442] been caused 898 by [CONTACT_19911]. The Medical Monitor also will make this assessment, which may or may not 899 agree with that of the study investigator. Reporting requirements will be based on the Medical 900 Monitor’s assessment as the Sponsor’s representative. 901 To ensure consistency of adverse event causality assessments, investigators should apply the 902 following general guideline when determining whether an adverse event is related: 903 • Unrelated: The AE is clearly not related to a study drug/device and a likely alternative 904 etiology exists such as an underlying disease, environmental or toxic factors or other 905 therapy. 906 • Unlikely Related: The AE does not follow a reasonable temporal sequence during or after 907 use of study drug/device and a more likely alternative etiology exists such as an 908 underlying disease, environmental or toxic factors, or other therapy.  909 • Possibly Related: The AE occurred in a reasonable time during or after use of study 910 drug/device; but could be related to another factor such as an underlying disease, 911 environmental or toxic factors, or other therapy; and there is a possible, though weak, 912 scientific basis for establishing a causal association between the AE and the study 913 drug/device. 914 • Probably Related: The AE occurred in a reasonable time during or after use of study 915 drug/device; is unlikely to be related to another factor such as an underlying disease, 916 environmental or toxic factors, or other therapy; and there is a plausible, though not 917 strong, scientific basis for establishing a causal association between the AE and the study 918 drug/device.  919 • Definitely Related: The AE occurred in a reasonable time during or after use of study 920 drug/device; cannot be explained by [CONTACT_3468], 921 environmental or toxic factors, or therapy; and there is a strong scientific basis for 922 establishing a causal association between the AE and the study drug/device.  923 • Not Assessable: Causality of an adverse event cannot be judged because information is [ADDRESS_600443] for relatedness and necessitate reporting as required (see [ADDRESS_600444]). 929 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 43 OF 58 7.2.6 Severity (Intensity)  of Adverse Events 930 The severity  (intensity) of an adverse event will be rated on a three point scale: (1) mild, (2) 931 moderate, or (3) severe.  A severity assessment is a clinical determination of the intensity of an 932 event. Thus, a severe adverse event is not necessarily serious.  For example, itching for several 933 days may be rated as severe, but may not be clinically serious. 934 • MILD: Usually transient, requires no special treatment, and does not interfere with the 935 participant’s daily activities. 936 • MODERATE: Usually causes a low level of inconvenience, discomfort or concern to the 937 participant and may interfere with daily activities, but is usually ameliorated by [CONTACT_3469] 938 therapeutic measures and participant is able to continue in study. 939 • SEVERE: Interrupts a participant’s usual daily activities, causes severe discomfort, may 940 cause discontinuation of study device, and generally requires systemic drug therapy or other 941 treatment. 942 7.2.7 Expectedness 943 For a serious adverse event that is considered possibly related to study device, the Medical 944 Monitor will classify the event as unexpected if the nature, severity, or frequency of the event is 945 not consistent with the risk information previously described in the approved labelling of the 946 study system.  947 7.2.8 Coding of Adverse Events 948 Adverse events will be coded using the MedDRA dictionary. To facilitate coding, the site will 949 enter a preliminary MedDRA code which the Medical Monitor may accept or change (the 950 Medical Monitor’s MedDRA coding will be used for all reporting). The Medical Monitor will 951 review the investigator’s assessment of causality and may agree or disagree.  Both the 952 investigator’s and Medical Monitor’s assessments will be recorded.  The Medical Monitor will [ADDRESS_600445] the final say in determining the causality as well as whether an event is classified as a 954 serious adverse event and/or an unanticipated adverse device effect. 955 7.2.9 Outcome of Adverse Events 956 The outcome of each reportable adverse event will be classified by [CONTACT_3470]: 957 • RECOVERED/RESOLVED – The participant recovered from the AE/SAE without sequelae.  [ADDRESS_600446] the AE/SAE stop date. 959 • RECOVERED/RESOLVED WITH SEQUELAE – The event persisted and had stabilized [ADDRESS_600447] the AE/SAE stop date. 961 • FATAL – A fatal outcome is defined as the SAE that resulted in death.  Only the event that 962 was the cause of death should be reported as fatal.  AEs/SAEs that were ongoing at the time 963 of death; however, were not the cause of death, will be recorded as “resolved” at the time of 964 death. 965 • NOT RECOVERED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is defined as 966 the event was ongoing with an undetermined outcome. 967 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 44 OF 58  An ongoing outcome will require follow-up by [CONTACT_3471] 968 outcome of the AE/SAE. 969  The outcome of an ongoing event at the time of death that was not the cause of death, 970 will be updated and recorded as “resolved” with the date of death recorded as the stop 971 date. 972 • UNKNOWN – An unknown outcome is defined as an inability to access the participant or 973 the participant’s records to determine the outcome (for example, a participant that was lost to 974 follow-up). 975 If any reported adverse events are ongoing when a participant completes the study (or 976 withdraws), adverse events classified as UADEs or related SAEs will be followed until they are [ADDRESS_600448] of improvement or change, even after the participant has 978 completed all applicable study visits/contacts. For all other adverse events, data collection will 979 end at the time the participant completes the study. Note: participants should continue to receive [ADDRESS_600449] not been met: 988 • CGM sensor needing replacement prior to labelled maximum use duration 989 • Infusion set needing replacement prior to labelled maximum use duration  990 • CGM tape adherence issues 991 • Pump infusion set insertion lasting fewer days than expected per manufacturer  992 • Battery lifespan deficiency due to inadequate charging or extensive wireless communication 993 • Intermittent device component disconnections/communication failures not requiring system 994 replacement or workaround/resolution not specified in user guide/manual. 995 • Device issues clearly addressed in the user guide manual that do not require additional [ADDRESS_600450] be reported by 999 the investigator to the Coordinating Center within 24 hours of the site becoming aware of the 1000 event.  This can occur via phone or email, or by [CONTACT_468514] 1001 form and device issue form if applicable. If the form is not initially completed, it should be 1002 competed as soon as possible after there is sufficient information to evaluate the event. All other 1003 reportable ADEs and other reportable AEs should be submitted by [CONTACT_468515] 1004 within 7 days of the site becoming aware of the event.  1005 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 45 OF 58 The Coordinating Center will notify all participating investigators of any adverse event that is 1006 serious, related, and unexpected. Notification will be made within 10 working days after the 1007 Coordinating Center becomes aware of the event. 1008 Each principal investigator [INVESTIGATOR_3411]-related adverse events and 1009 abiding by [CONTACT_66716]/her Institutional Review Board or [ADDRESS_600451] report all serious, 1011 related adverse events within seven calendar days. 1012 Upon receipt of a qualifying event, the Sponsor will investigate the event to determine if a 1013 UADE is confirmed, and if indicated, report the results of the investigation to all overseeing 1014 IRBs, and the FDA within 10 working days of the Sponsor becoming aware of the UADE per 1015 21CFR 812.46(b) (2).  The Sponsor in conjunction with the Medical Monitor must determine if [ADDRESS_600452] receipt notice of the UADE. The investigator(s) may then be required to [ADDRESS_600453] led to a UADE, including device deficiencies, irrespective of whether an adverse 1024 event occurred. 1025 Device malfunctions will be handled by [CONTACT_263243].  In the case 1026 of a CGM transmitter or sensor device malfunction, information will be forwarded to Dexcom by 1027 the site personnel, to be handled by [CONTACT_468516]. 1028 7.5 Safety Oversight 1029 The study Medical Monitor will review all adverse events and adverse device events that are 1030 reported during the study.  SAEs typi[INVESTIGATOR_66684] 24 hours of reporting.  1031 Other AEs typi[INVESTIGATOR_3413] a weekly basis. Additionally, the Medical Monitor will 1032 review compi[INVESTIGATOR_27985]. 1033 The Clinical Study Director will be informed of all cases of severe hypoglycemia and DKA 1034 and the Medical Monitor’s assessment of relationship to the study device; and informed of all 1035 reported device issues. 1036 7.6 Stoppi[INVESTIGATOR_2121] 1037 7.6.1 Participant Discontinuation of Study Device 1038 In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or DKA 1039 event (or a malfunction that could have led to severe hypoglycemia or DKA), use of closed-loop 1040 mode will be suspended while the problem is diagnosed. The UADE will be reported to the IRB 1041 and FDA. After assessment of the problem and any correction,  use of closed-loop mode will not 1042 be restarted until approval is received from the IRB and FDA. 1043 In the absence of a device malfunction, a participant will be discontinued from the study if any of 1044 the following occur:  1045 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 46 OF 58 • The investigator believes it is unsafe for the participant to continue on the intervention.  This 1046 could be due to the development of a new medical condition or worsening of an existing 1047 condition; or participant behavior contrary to the indications for use of the device that 1048 imposes on the participant’s safety 1049 • The participant requests that the treatment be stopped 1050 • Participant pregnancy 1051 • Two distinct epi[INVESTIGATOR_3414], HHS, or severe hypoglycemia as defined above, so only a [ADDRESS_600454] 1054 to determination of cause and whether the occurrence of the event can be attributed to use of the 1055 study device.  1056 An additional requirement for continued study participation following a single DKA or severe 1057 hypoglycemia event will be that (1) the site investigator believes that the event is explainable, 1058 unlikely to recur, and that it is safe for the participant to continue to use the system and (2) the 1059 Medical Monitor concurs. If the Medical Monitor determines that the occurrence of the event 1060 indicates that it is not safe for the participant to continue to use the study system, the participant 1061 will be discontinued from the study. 1062 Even if the study device system is discontinued, the participant will be encouraged to remain in 1063 the study through the final study visit. 1064 7.6.2 Criteria for Suspending or Stoppi[INVESTIGATOR_3396] 1065 In addition to the suspension of closed-loop mode use due to a UADE as described above, 1066 closed-loop system use will be suspended if there are three or more cases of severe 1067 hypoglycemia or three or more cases of hyperglycemia/ketotic events qualifying as SAEs across [ADDRESS_600455] initiated Control-IQ technology use. 1069 Study activities could be similarly suspended if the manufacturer of any constituent study device 1070 requires stoppage of device use for safety reasons (e.g. product recall).  The affected study 1071 activities may resume if the underlying problem can be corrected by a protocol or system 1072 modification that will not invalidate the results obtained prior to suspension. 1073   1074 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 47 OF 58 Chapter 8: Miscellaneous Considerations [ADDRESS_600456] one of these insulins available to them for use. 1079 8.2 Collection of Medical Conditions and Medications 1080 Pre-Existing Condition: Any medical condition that is either present at screening, a chronic [ADDRESS_600457] the participant’s health during the course of the 1082 study (e.g., prior myocardial infarction or stroke). 1083 Medical Conditions during the study: In addition to conditions meeting the reporting 1084 requirements for an adverse event or device issue as described above, the following medical 1085 conditions should also be reported: (1) new diagnosis of a chronic disease (i.e., not present at the 1086 time of enrollment), and (2) any medical condition that could affect the participant’s ability to [ADDRESS_600458] an outcome assessment. 1088 Medications: All medication for the treatment of chronic pre-existing conditions, medical 1089 conditions (including medical conditions that do not require recording), and/or adverse events [ADDRESS_600459] their personal 1097 physician to change their prescribed personal insulin to lispro or aspart for the duration of the 1098 trial. 1099 Afrezza (inhaled insulin) or concurrent use of basal insulins will not be permitted during device 1100 use in the trial. Additional medications to treat glycemia (such as SGL-2 inhibitors or GLP-1 1101 receptor agonists), commonly used by [CONTACT_468517] [ADDRESS_600460] 3 months. No new medications for weight loss may be added during the 1107 trial. 1108 Additional medications may be excluded per judgement of the investigator. 1109 The investigational study devices (study insulin pump, study CGM system) must be removed 1110 before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) or diathermy treatment. [ADDRESS_600461] a commercially available glucagon (or glucagon analog) 1119 preparation for treatment as needed of severe hypoglycemia. 1120 8.7 Pregnancy Reporting 1121 If pregnancy occurs, the participant will be discontinued from the study.  The occurrence of 1122 pregnancy will be reported to the Coordinating Center within seven days and to the JCHR IRB as 1123 an Unanticipated Problem within seven calendar days.  1124 8.8 Participant Compensation 1125 Participant compensation will be specified in the informed consent form. 1126 8.9 Participant Withdrawal 1127 Participation in the study is voluntary, and a participant may withdraw at any time.  For 1128 participants who withdraw, their data will be used up until the time of withdrawal. 1129 8.10 Confidentiality 1130 For security and confidentiality purposes, participants will be assigned an identifier that will be 1131 used instead of their name.  Protected health information gathered for this study will be shared 1132 with the coordinating center, the Jaeb Center for Health Research in Tampa, FL.  De-identified 1133 participant information may also be provided to research sites involved in the study.1134 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 49 OF 58 Chapter 9: Statistical Considerations 1135 9.1 Statistical and Analytical Plans 1136 The approach to sample size and statistical analyses are summarized below.   1137 9.2 Statistical Hypotheses 1138 The primary outcomes for this study are CGM-measured percentage below 54 mg/dl and CGM-1139 measured percent above 180 mg/dl over a 6-week period. The intervention will be considered 1140 effective if the 6-week follow-up % above 180 mg/dl value is superior and % below 54 mg/dl 1141 value is non-inferior to the corresponding baseline values using a statistical significance of 1142 α=0.05 and the analysis specified below in Section 6 (i.e., p < 0.05). 1143 The null/alternative hypotheses are: 1144  1145 Percentage below 54 mg/dl: 1146 a. Null Hypothesis: The difference in mean CGM-measured % below 54 mg/dl between the 1147 6 weeks follow-up and baseline is greater than or equal to +1% (non-inferiority). 1148 b. Alternative Hypothesis: The difference in mean CGM-measured % below 54 mg/dl 1149 between the 6 weeks follow-up and baseline is less than +1%. 1150  1151 Percentage above 180 mg/dl: 1152 a. Null Hypothesis: There is no difference in mean CGM-measured % above 180 mg/dL 1153 between the 6 weeks of follow-up and baseline (superiority).  1154 b. Alternative Hypothesis: The mean CGM-measured % above 180 mg/dL is different at 1155 baseline than the mean over 6 weeks of follow-up. 1156  1157 9.3 Sample Size 1158 The planned cohort of N=[ADDRESS_600462] N=24 completing the study is a 1159 convenience sample not based on statistical principles. 1160 9.4 Outcome Measures 1161 9.4.1 Primary Efficacy Endpoints 1162 • CGM-measured percentage below 54 mg/dl 1163 • CGM measured percentage above 180 mg/dl 1164 9.4.2 Secondary Efficacy Endpoints 1165 • CGM-measured metrics: 1166 ➢ Percentage in range 70-180 mg/dL 1167 ➢ Percentage < 70 mg/dL 1168 ➢ Percentage > 250 mg/dL 1169 ➢ Percentage in tight glycemic range 70-140 mg/dL 1170 ➢ Mean glucose 1171 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 50 OF 58  1172 ➢ Up to 4hr post-prandial glycemic metrics: 1173 ▪ Peak  1174 ▪ Area Under the Curve (AUC) 1175  1176 • Insulin metrics 1177 ➢ Total daily insulin use 1178 ➢ Total basal insulin 1179 ➢ Total bolus insulin 1180 • Weight 1181 • Questionnaires  1182 ➢ Tandem Study-Specific Baseline Survey  1183 ➢ Altarum Consumer Engagement Measure 1184 ➢ Tandem Pump Training Survey 1185 ➢ DAWN Impact of Diabetes Profile 1186 ➢ Diabetes Impact and Device Satisfaction Scale 1187 ➢ PROMIS Sleep-Related Impairment Questionnaire 1188 ➢ System Usability Scale 1189  1190 Calculation of CGM metrics 1191 • Baseline values will be taken from the last [ADDRESS_600463] 24hr of data during this baseline period are required 1194 for the glycemic metrics to be calculated. 1195 • Follow-up values will be calculated using CGM data from the 6-week period of CLC use. [ADDRESS_600464] 168 hours of CGM data available 1197 during the 6-week CLC use period. 1198 • Exploratory analyses will include all CGM data between the initiation of Open-Loop use [ADDRESS_600465] 24hr of data during this period are required for 1200 the glycemic metrics to be calculated. 1201 • Separate values for each CGM metric (except for post-prandial peak and 4-hour AUC) 1202 will be calculated for: 1203 ➢ Overall: 24 hours of the day 1204 ➢ Daytime: CGM readings from 6:00 am – 11:59 pm 1205 ➢ Nighttime: CGM readings from midnight – 5:59 am 1206 ➢ During logged exercise challenges 1207 9.4.3 Safety Endpoints 1208 • Severe hypoglycemia (needing assistance) 1209 • DKA 1210 • Hyperosmolar Hyperglycemic Syndrome 1211 • Serious Adverse Events 1212 • Unanticipated adverse device effects  [ADDRESS_600466] 80% of the 1219 time during the 6-week period. If fewer than 10% of the study participants would be excluded 1220 based on this criterion, then the per-protocol analysis will not be performed. 1221  1222 Safety analyses will include all participants. 1223 9.6 Analysis of the Primary Efficacy Endpoint(s) 1224 Summary statistics appropriate to the distribution (e.g., mean and standard deviation, or median 1225 and quartiles) will be for each of the primary efficacy endpoints (CGM-measured percentage 1226 below 54 mg/dl and percentage above 180 mg/dl) at baseline, during CLC use, and for the [ADDRESS_600467] for each metric. If the 1231 paired differences (i.e., change values) do not follow an approximate normal distribution, then a [ADDRESS_600468]-prandial CGM metrics (4 hour 1237 peak and AUC) and during exercise challenges, there will be no corresponding pre-study 1238 baseline. Descriptive analyses of these metrics will be limited to values during CLC use. 1239 9.8 Safety Analyses 1240 All participants will be included in the safety analyses. All adverse events will be tabulated with 1241 separate lists for events that occur before, during OL, and during CLC use. 1242  1243 Additionally, the number of events and the event rate per 100 person-years during CLC use will 1244 be calculated for each of the safety outcomes listed above: 1245 • Severe hypoglycemia (needing assistance) 1246 • DKA 1247 • Hyperosmolar Hyperglycemic Syndrome 1248 • All Serious Adverse Events 1249 • Unanticipated adverse device effects  1250  1251 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 52 OF 58 9.9 Intervention Adherence 1252 Descriptive summary statistics will be given for the percentage of time that the CLC is in active 1253 mode and the amount of CGM use over the 6-week period. A scatterplot of these two 1254 percentages will be constructed. Boxplots will be given for each of these percentages for each of 1255 the 6 weeks of follow-up. Descriptive statistics will be given for the percentage of time spent in 1256 each of the CLC operational modes.  1257 9.10 Protocol Adherence and Retention 1258 The following measures of adherence will be tabulated during the 6-week follow-up period: 1259 • Number of protocol and procedural deviations  1260 • Flow chart accounting for all enrolled participants up to the end of study 1261 • Flow chart of all enrolled participants at all scheduled visits and phone contacts post 1262 treatment initiation 1263 • Number of and reasons for unscheduled visits and phone calls 1264 • Number of participants who stopped OL or CLC use and reasons 1265  1266 9.11 Baseline Descriptive Statistics 1267 Baseline demographic and clinical characteristics of the cohort of all enrolled participants will be 1268 summarized in a table using summary statistics appropriate to the distribution of each variable. 1269 Descriptive statistics will be displayed for the following: 1270 • Age 1271 • Sex 1272 • Race/Ethnicity 1273 • Diabetes duration 1274 • Insulin method before enrollment (basal only or multiple daily injections) 1275 • CGM use before enrollment 1276 • HbA1c 1277 • BMI 1278 • Participant-reported number of SH and DKA 12 months prior to the start of the study 1279 • Baseline CGM metrics including: 1280 • % time < 54 mg/dl 1281 • % time > 180 mg/dl 1282 • % in range 70-180 mg/dl 1283 • mean glucose 1284 • % time < 70 mg/dl 1285  1286 9.12 Device Issues 1287 The following tabulations and analyses will be performed to assess device issues: 1288 • Device malfunctions requiring study team contact [CONTACT_91120] 1289 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 53 OF 58 • Rate of different failure events and alarms per 24 hours recorded by [CONTACT_418104]-IQ system – 1290 overall and by [CONTACT_95839] 1291 9.13 Planned Interim Analyses 1292 No formal interim efficacy analyses are planned. 1293 9.14 Sub-Group Analyses 1294 In exploratory analyses, the primary outcomes (percent <54 mg/dl and percent >180 mg/dl) will [ADDRESS_600469] squares regression will be fit with the dependent 1296 variable being the paired difference (value during CLC use minus value at baseline) and the 1297 subgroup factor as an independent variable. 1298 Interpretation of subgroup analyses will be viewed with caution, particularly in the absence of an 1299 overall significant difference. Subgroups will be analyzed according to the following baseline 1300 factors: 1301 • Gender 1302 • Race/Ethnicity (if sufficient numbers in more than one category) 1303 • Insulin 1304 ➢ Basal only (Group A) 1305 ➢ Multiple daily injections (Group B) 1306 9.15 Multiple Comparison/Multiplicity 1307 There will be no formal correction for multiple comparisons in this pi[INVESTIGATOR_799]. 1308 9.16 Exploratory Analyses 1309 The primary analysis described above in Section 9.6 will be repeated with the CGM-measured 1310 percentage below 54 mg/dl and percentage above 180 mg/dl during follow-up limited to times 1311 when the CLC was in active mode. 1312 Weekly boxplots for selected glycemic and insulin metrics will be generated. 1313 In addition to the baseline and 6 weeks CLC use period, the glycemic and insulin analyses will 1314 be extended to include the 2-4 weeks of OL use. Only descriptive summary statistics and plots 1315 will be generated for these new analyses. 1316 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 54 OF 58 Chapter 10: Data Collection and Monitoring 1317 10.1 Case Report Forms and Other Data Collection 1318 The main study data are collected on electronic case report forms (CRFs). When data are directly 1319 collected in electronic case report forms, this will be considered the source data. For any data 1320 points for which the eCRF is not considered source (e.g. lab results that are transcribed from a 1321 printed report into the eCRF), the original source documentation must be maintained in the 1322 participant’s study chart or medical record. This source must be readily verifiable against the [ADDRESS_600470] be recorded (e.g., office note, visit record, 1325 etc.)    [ADDRESS_600471].  These documents should 1336 be retained for a longer period, however, if required by [CONTACT_427].  No records will be 1337 destroyed without the written consent of the sponsor, if applicable.  It is the responsibility of the 1338 sponsor to inform the investigator when these documents no longer need to be retained. 1339 10.3 Quality Assurance and Monitoring 1340 Designated personnel from the Coordinating Center will be responsible for maintaining quality 1341 assurance (QA) and quality control (QC) systems to ensure that the clinical portion of the trial is 1342 conducted and data are generated, documented and reported in compliance with the protocol, 1343 Good Clinical Practice (GCP) and the applicable regulatory requirements, as well as to ensure 1344 that the rights and wellbeing of trial participants are protected and that the reported trial data are 1345 accurate, complete, and verifiable.  Adverse events will be prioritized for monitoring. 1346 A risk-based monitoring (RBM) plan will be developed and revised as needed during the course 1347 of the study, consistent with the FDA “Guidance for Industry Oversight of Clinical 1348 Investigations — A Risk-Based Approach to Monitoring” (August 2013).  Study conduct and 1349 monitoring will conform with 21 Code of Federal Regulations (CFR) 812. This plan describes in [ADDRESS_600472] importance for monitoring at the site are participant eligibility and adverse 1353 events.  Therefore, the RBM plan will focus on these areas.  As much as possible, remote 1354 monitoring will be performed in real-time with on-site monitoring performed to evaluate the 1355 verity and completeness of the key site data.  Elements of the RBM may include: 1356 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 55 OF 58 • Qualification assessment, training, and certification for sites and site personnel 1357 • Oversight of Institutional Review Board (IRB) coverage and informed consent procedures 1358 • Central (remote) data monitoring: validation of data entry, data edits/audit trail, protocol 1359 review of entered data and edits, statistical monitoring, study closeout 1360 • On-site monitoring (site visits): source data verification, site visit report 1361 • Agent/Device accountability 1362 • Communications with site staff 1363 • Patient retention and visit completion 1364 • Quality control reports 1365 • Management of noncompliance 1366 • Documenting monitoring activities 1367 • Adverse event reporting and monitoring [ADDRESS_600473] access to all trial related sites, source 1372 data/documents, and reports for the purpose of monitoring and auditing by [CONTACT_456], and 1373 inspection by [CONTACT_3482]. 1374 10.4 Protocol Deviations 1375 A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or procedure 1376 requirements.  The noncompliance may be either on the part of the participant, the investigator, 1377 or the study site staff.  A significant (or major) deviation is any deviation that departs from the [ADDRESS_600474] that it poses an increase in the risk to subjects, adversely 1379 affects the welfare, rights, or safety of the research subjects, or negatively influences the 1380 scientific study integrity. As a result of a significant deviation, a corrective and preventive action 1381 plan shall be developed by [CONTACT_3483]. 1382 The site PI/study staff is responsible for knowing and adhering to their IRB requirements.  1383 Further details about the handling of protocol deviations will be included in the monitoring plan. 1384 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 56 OF 58 Chapter 11: Ethics/Protection of Human Participants [ADDRESS_600475] 1386 The investigator will ensure that this study is conducted in full conformity with Regulations for 1387 the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 1388 21 CFR Part 56, and/or the ICH E6. 1389 11.2 Institutional Review Boards 1390 The protocol, informed consent form(s), recruitment materials, and all participant materials will [ADDRESS_600476] be obtained before any participant is enrolled.  Any amendment to the protocol will 1393 require review and approval by [CONTACT_3484].  All 1394 changes to the consent form will be IRB approved; a determination will be made regarding 1395 whether previously consented participants need to be re-consented. 1396 11.3 Informed Consent Process 1397 11.3.1 Consent Procedures and Documentation 1398 Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 1399 the study and continues throughout the individual’s study participation.  Extensive discussion of [ADDRESS_600477] by [CONTACT_3486], their staff, 1416 and the sponsor(s) and their agents.  This confidentiality is extended to cover testing of [ADDRESS_600478] all documents and records 1423 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 57 OF 58 required to be maintained by [CONTACT_093], including but not limited to, medical records 1424 (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study.  The clinical 1425 study site will permit access to such records. 1426 The study participant’s contact [CONTACT_3487] 1427 internal use during the study.  At the end of the study, all records will continue to be kept in a 1428 secure location for as long a period as dictated by [CONTACT_3488], institutional policies, or 1429 sponsor requirements. 1430 Study participant research data, which is for purposes of statistical analysis and scientific 1431 reporting, will be transmitted to and stored at the Jaeb Center for Health Research (JCHR).  This 1432 will not include the participant’s contact [CONTACT_1290], unless otherwise specified in [ADDRESS_600479] 1436 protected.  At the end of the study, all study databases will be archived at the JCHR. 1437 
JAEB CENTER FOR HEALTH RESEARCH 
2IQ PROTOCOL V3.0 PAGE 58 OF 58 Chapter 12: References 1438 1. Morberg JN, Singh H, McElwee-Malloy M, Habif S, Constantin A. Real-World 1439 Evaluation of Glycemic Outcomes by [CONTACT_3489] 1 and Type 2 1440 Diabetes Onboarding to Control-IQ Technology. Diabetes. 2021; 70(Supplement 1):710-1441 P. 1442 2. Breton MD, Kovatchev BP. One Year Real-World Use of the Control-IQ Advanced 1443 Hybrid Closed-Loop Technology. Diabetes Technol Ther. 2021; 1444 3. Brown SA, Kovatchev BP, Raghinaru D, Lum JW et al. Six-month randomized, 1445 multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019; 1446 381(18):1707-1717.  1447 4. Breton MD, Kanapka LG, Beck RW, Ekhlaspour L et al. A randomized trial of closed-1448 loop control in children with type 1 diabetes. N Engl J Med. 2020; 383(9):836-845.  1449  1450 